Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sage Therapeutics, Inc.
< Previous
1
2
Next >
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 22, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 16, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
February 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
February 02, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
January 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
January 03, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
December 06, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 23, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
November 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 09, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
November 08, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 25, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
October 17, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
September 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
August 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Upcoming August Investor Conferences
August 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
July 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Upcoming June Investor Conferences
June 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
June 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
May 03, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
May 02, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
BIIB
SAGE
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
April 19, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
April 01, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics to Present at 2022 Stifel CNS Days
March 22, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
March 15, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
February 24, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
February 16, 2022
From
Sage Therapeutics, Inc.
Via
Business Wire
Tickers
SAGE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.